DailyIQ
|
Sector:HealthcareAll sectors
Last updated 23 minutes ago

INSM·INSM

$.
+. (+.%)
After Hours
High
$152.19
Open
$147.24
Market Cap
31.72B
52W High
$212.75
Low
$144.50
P. Close
$107.40
P/E
-
52W Low
$60.40
Fwd P/E
-
Mean Target
-
Technical Score (1D)
36
SELL
News Sentiment
72
BULLISH
Affinity Asset Advisors recently increased its stake in Apogee Therapeutics and initiated a position in Praxis Precision Medicines, reflecting a positive outlook on the biotech sector. This is relevant because INSM is a significant holding within the fund's portfolio, suggesting continued investor interest in the space. The fund's actions may signal positive sentiment towards the biotech sector, potentially impacting INSM. Investors are closely monitoring INSM's drug pipeline, regulatory progress, and partnerships, which influence short-term volatility. Despite recent declines, INSM shares maintain strong long-term returns, indicating continued investor interest. Valuation methods are being used to assess the company's value, and the market is tracking the company's drug pipeline and regulatory milestones. These factors contribute to short-term volatility, while the stock's long-term performance remains robust.
Earnings Summary
Insmed Incorporated develops and commercializes therapies for serious and rare diseases in the United States, Europe, Japan, and internationally, operating within the healthcare biotechnology sector. The provided earnings data only includes Q4 2024 and Q4 2025. In Q4 2024, the company missed EPS estimates. Not enough information is available to compare recent quarterly performance. Not enough information is available to analyze historical streak analysis. Recent news indicates that Insmed will release its Q4 and full-year 2025 financial results on February 19, 2026, followed by a conference call. The market will likely react to the financial results and management's commentary on the company's progress. Analysts project Insmed to reach profitability in 2027, but the company is currently operating at a loss. Investors should watch the actual earnings results against expectations and assess the impact of insider moves. Additionally, analysts project Insmed to reach profitability in 2027, but the company is currently operating at a loss.

EPS

EstBeatMiss
$-1.60$-1.47$-1.33$-1.20$-1.07Q4'24Q4'25
QtrEstActual+/−
Q4'25$-1.13$-1.54-36.4%
Q4'24$-1.16$-1.32-13.3%

Revenue

EstBeatMiss
$81M$132M$184M$236M$288MQ4'24Q4'25
QtrEstActual+/−
Q4'25$226M$264M+16.6%
Q4'24 - $104M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

INSM Stock Snapshot

INSM is currently trading at $106.95, giving INSM a market cap of 31.72B. Today's range spans $144.50–$152.19, with shares opening at $147.24 and moving down $0.45 (0.4%) from the prior close. DailyIQ's technical score sits at 36/100 (HOLD) with a news sentiment reading of 72/100.

Over the past year INSM has traded between $60.40 and $212.75 - the current price is +77.1% off the 52-week low and -49.7% from the high.

INSM (INSM) has 31.72B in Healthcare market capitalization and is currently neutral on the technical dashboard: 36/100, HOLD, price $106.95 (in the lower half of its 52-week range). Sentiment reads bullish at 72/100. In this tier, quiet accumulation often happens in HOLD phases - active managers who want to build positions without signaling do it here, where the price isn't trending and volume patterns are easier to hide. Annual range: $60.40–$212.75.

Portfolio construction in Healthcare often uses large-cap names like INSM as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 36/100 (HOLD) at $106.95 (in the lower half of its 52-week range) and bullish sentiment (72/100) frame the position as a catalyst play within the $60.40–$212.75 annual range rather than a directional bet.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…